Intensifying ADT in mHSPC: How to Improve Patient Outcomes and Adherence

Intensifying ADT in mHSPC: How to Improve Patient Outcomes and Adherence is organized by Global Oncology Academy (GOA).

Publication Dates
Release Date: 09/29/2023
Expiration Date: 09/29/2024

Description:
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.

This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.

Learning Objectives:
After participating in this educational activity, participants should be better able to:
• Evaluate recent practice-changing clinical trial data and guideline recommendations for ADT intensification in the treatment of patients with mHSPC
• Implement a shared-decision making approach in practice to inform treatment selection and sequencing to maximize exposure to life-prolonging therapies for patients with mHSPC
• Explain the roles and responsibilities of oncology pharmacists and nurses in an interdisciplinary care model for patients with mHSPC
• Incorporate interdisciplinary strategies to reduce barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer